RETROSPECTIVE RE- IDENTIFICATION OF CANDIDA STRAINS BY MALDI-TOF IN SEEK OF CANDIDA AURIS

Authors

  • Zoya Ivanova National Center of Infectious and Parasitic Diseases Author
  • Ivva Philipova National Center of Infectious and Parasitic Diseases Author https://orcid.org/0000-0003-4299-4827
  • Lyubomira Boyanova National Center of Infectious and Parasitic Diseases Author
  • Todor Kantardjiev National Center of Infectious and Parasitic Diseases Author

DOI:

https://doi.org/10.58395/pipd.v50i2.90

Keywords:

C. auris, MALDI-TOF, candidemia, antifungal resistance, Bulgaria

Abstract

The yeast C. auris was first described as a new species in 2009. Since then, this species was recognized as an emerging multi-drug-resistant (MDR) yeast that can cause a wide spectrum of infections, ranging from fungemia to deep-seated infections, especially in intensive care settings. It can be not- or misidentified by commercial identification systems. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) has recently been considered as a convenient, rapid and accurate technology in the identification of yeast isolates to species level. A total of 132 clinical isolates, collected from 2015 to 2021 in the National Reference Laboratory of Mycology and Sexually Transmitted Infections were included in the study. The isolates were mainly from patients with candidemia and other specimens from invasive Candida infections.

The isolates were identified by standard mycological procedures, the assimilation profile was done by commercially available strips and with the automated VITEK2 Compact system. All the strains were identified with MALDI-TOF MS. Antifungal susceptibility testing was conducted to some of the strains by agar disk-diffusion (according to CLSI M44-A2), E-test and VITEK2.

Some of the strains which could not be identified or were misidentified by standard mycological procedures were correctly determined by MALDI-TOF MS. None of them was identified as C. auris. There were no large deviations in the antifungal susceptibility profiles of the tested strains.

We assess MALDI-TOF MS as convenient, rapid, cost- effective and accurate technology in the identification of fungal strains which are difficult to determine with the traditional procedures. Up to now, isolation of C. auris has not been reported in Bulgaria.

Downloads

Download data is not yet available.

References

Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41–4. DOI: https://doi.org/10.1111/j.1348-0421.2008.00083.x DOI: https://doi.org/10.1111/j.1348-0421.2008.00083.x

Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49(9):3139–42. DOI: https://doi.org/10.1128/JCM.00319-11 DOI: https://doi.org/10.1128/JCM.00319-11

Ge M-C, Kuo A-J, Liu K-L, Wen Y-H, Chia J-H, Chang P-Y, et al. Routine identification of microorganisms by matrix-assisted laser desorption ionization time-of-flight mass spectrometry: Success rate, economic analysis, and clinical outcome. J Microbiol Immunol Infect [Internet]. 2017;50(5):662–8. Available from: https://www.sciencedirect.com/science/article/pii/S1684118216300639. DOI: https://doi.org/10.1016/j.jmii.2016.06.002 DOI: https://doi.org/10.1016/j.jmii.2016.06.002

Arastehfar A, Daneshnia F, Kord M, Roudbary M, Zarrinfar H, Fang W, et al. Comparison of 21-Plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA sequencing for a wide range of clinically isolated yeast species: Improved identification by combining 21-Plex PCR and API 20C AUX as an alternative strategy for developing countries. Front Cell Infect Microbiol. 2019;9:21. DOI: https://doi.org/10.3389/fcimb.2019.00176 DOI: https://doi.org/10.3389/fcimb.2019.00021

Stathi A, Loukou I, Kirikou H, Petrocheilou A, Moustaki M, Velegraki A, et al. Isolation of Candida auris from cystic fibrosis patient, Greece, April 2019. Eurosurveillance. 2019;24(29):1900400. DOI: https://doi.org/10.2807/1560-7917.ES.2019.24.29.1900400 DOI: https://doi.org/10.2807/1560-7917.ES.2019.24.29.1900400

Cassagne C, Normand A, l’Ollivier C, Ranque S, Piarroux R. Performance of MALDI-TOF MS platforms for fungal identification. Mycoses. 2016;59(11):678–90. DOI: https://doi.org/10.1111/myc.12506 DOI: https://doi.org/10.1111/myc.12506

Pulcrano G, Iula DV, Vollaro A, Tucci A, Cerullo M, Esposito M, et al. Rapid and reliable MALDI-TOF mass spectrometry identification of Candida non-albicans isolates from bloodstream infections. J Microbiol Methods.2013;94(3):262–6.DOI: https://doi.org/10.1016/j.mimet.2013.07.001 DOI: https://doi.org/10.1016/j.mimet.2013.07.001

Lu J-J, Lo H-J, Lee C-H, Chen M-J, Lin C-C, Chen Y-Z, et al. The use of MALDI-TOF mass spectrometry to analyze commensal oral yeasts in nursing home residents. Microorganisms. 2021;9(1):142.DOI: https://doi.org/10.3390/microorganisms9010142 DOI: https://doi.org/10.3390/microorganisms9010142

Kouzmanov A, Philipova I, Ivanova Z, Ivanov I, Kantardjiev V. DNA sequencing of its region for rapid and accurate identification of medically important fungi. Probl Infect Parasit Dis. 2016 Jan 1;44:19–22.

Downloads

Published

2023-02-19

Issue

Section

Articles

How to Cite

(1)
Ivanova, Z.; Philipova, I.; Boyanova, L.; Kantardjiev, T. RETROSPECTIVE RE- IDENTIFICATION OF CANDIDA STRAINS BY MALDI-TOF IN SEEK OF CANDIDA AURIS. Probl Infect Parasit Dis 2023, 50 (2), 8-12. https://doi.org/10.58395/pipd.v50i2.90.